Pancreatic Cancer and Genetic Testing: What to Know About Your Risk and Your Family's

By Amanda Shrewsbury, MS, CGC

The topic of pancreatic cancer carries weight. It can often be emotional and sparks the significant conversation of genetic testing in a unique way.

For some people, that conversation begins because a parent, sibling, or other close relative has been diagnosed, and the question of whether the rest of the family should be tested becomes urgent in a way it had not been before. For others, the conversation begins with their own diagnosis, when an oncologist mentions genetic testing as part of the treatment plan and the question becomes what those results might mean for their cancer diagnosis and for their family. Both of these conversations matter, and the answers have shifted meaningfully in the last several years as guidelines have evolved and as more genes have been identified.

This post is for both audiences. We will walk through what is currently known about hereditary pancreatic cancer, which genes are involved, what current testing recommendations look like, what "familial pancreatic cancer kindred" means and why it matters, and what screening options exist for people at elevated risk.

Is pancreatic cancer hereditary?

For most people, pancreatic cancer is not hereditary. The majority of cases are sporadic, meaning they happen in the absence of an identifiable inherited cause. But a meaningful minority are connected to inherited genetic factors. Current research suggests that approximately 5 to 10 percent of people diagnosed with pancreatic adenocarcinoma (the most common type of pancreatic cancer) carry a pathogenic variant in a hereditary cancer gene (Hu et al., 2018).

It is helpful to distinguish three categories of pancreatic cancer when thinking about genetics:

  • Sporadic pancreatic cancer. The majority of cases. No identified inherited cause and no significant family history pattern.
  • Familial pancreatic cancer. A family history pattern of pancreatic cancer that suggests an inherited factor, but where genetic testing has not identified a specific pathogenic variant.
  • Hereditary pancreatic cancer. A pathogenic variant in a known cancer susceptibility gene has been identified and explains the elevated risk.

This post focuses on the hereditary and familial categories, because those are where genetic counseling, testing, and proactive screening have the most to offer. The "familial without an identified gene" category is particularly important to recognize, because the recommendations for those families are not always the same as the recommendations for people who test negative on a hereditary cancer panel. We will return to that distinction later.

What genes are associated with pancreatic cancer risk?

Multiple genes have been associated with elevated pancreatic cancer risk. The most commonly implicated include:

  • BRCA1 and BRCA2 — The two genes most associated with Hereditary Breast and Ovarian Cancer (HBOC) syndrome also confer elevated lifetime pancreatic cancer risk. The risk is more pronounced for BRCA2 (estimated at 5 to 10 percent lifetime) than for BRCA1 (estimated at 2 to 5 percent lifetime) (FORCE, 2025; NCCN, 2025). Our BRCA1 and BRCA2 explained post goes into detail on the full risk profile.
  • PALB2 — A partner gene to BRCA2 with overlapping function in DNA repair. Lifetime pancreatic cancer risk is estimated at 2 to 5 percent (FORCE, 2025; Yang et al., 2020). Covered in more depth in our post on hereditary cancer genes beyond BRCA1, BRCA2, and Lynch syndrome.
  • ATM — Lifetime pancreatic cancer risk approximately 5 to 10 percent, with the largest cohort study to date placing the cumulative risk at 9.5 percent by age 80 (Hsu et al., 2021).
  • The Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) — Lynch syndrome elevates pancreatic cancer risk along with the more commonly known colorectal and endometrial cancers. Lifetime pancreatic cancer risk varies by gene but is generally estimated at 1 to 5 percent (FORCE, 2025; NCCN, 2025). Our Lynch syndrome explained post covers this in depth.
  • CDKN2A — Associated with familial atypical multiple mole melanoma syndrome (FAMMM), a hereditary cancer syndrome involving melanoma and pancreatic cancer. Lifetime pancreatic cancer risk is estimated at 17 to 25 percent in CDKN2A carriers, which is among the highest of the genes on this list (FORCE, 2025; Vasen et al., 2000).
  • STK11 — Associated with Peutz-Jeghers syndrome, which carries one of the highest lifetime pancreatic cancer risks of any hereditary cancer syndrome, estimated at approximately 11 to 36 percent (FORCE, 2025; Hearle et al., 2006).
  • TP53 — Associated with Li-Fraumeni syndrome, with a smaller but real elevated pancreatic cancer risk among the broader Li-Fraumeni cancer spectrum.

Modern multigene panels test for all of these genes (and more) at once, which is the standard of care today.

Does NCCN recommend genetic testing for everyone diagnosed with pancreatic cancer?

Yes. Current National Comprehensive Cancer Network (NCCN) guidelines recommend that germline genetic testing be offered to every person diagnosed with pancreatic adenocarcinoma, regardless of age at diagnosis, family history, or any other criteria (NCCN, 2025). This is a meaningful shift from earlier guidelines, which limited testing to people who met specific family history or age-of-diagnosis thresholds.

The shift was driven in significant part by research showing that family history alone is not a reliable predictor of who carries a pathogenic variant. In the largest study to date, 5.5 percent of people diagnosed with pancreatic cancer carried a pathogenic variant in one of six cancer susceptibility genes, and 5.2 percent of people without any family history of pancreatic cancer also carried a pathogenic variant (Hu et al., 2018). Restricting testing to people with a clear family history was missing meaningful numbers of carriers.

Testing at the time of diagnosis matters for two reasons. First, results can shape treatment, particularly for people with BRCA1, BRCA2, or PALB2 variants, who may be candidates for PARP inhibitor therapy, a class of targeted treatments that work by exploiting DNA repair defects in tumors carrying these variants. The POLO trial established olaparib as a maintenance therapy for people with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed after platinum-based chemotherapy, based on improved progression-free survival (Kindler et al., 2022). Second, results have implications for relatives, who may benefit from their own testing and from screening if they also carry the variant.

Should you get genetic testing if a family member had pancreatic cancer?

NCCN testing criteria for people who have not been diagnosed with cancer but who have a family history of pancreatic cancer are broader than many people realize. Genetic testing is recommended or may be considered for any of the following scenarios:

  • One or more first-degree relatives (a parent, sibling, or child) with pancreatic cancer.
  • Two or more relatives on the same side of the family with pancreatic cancer, regardless of how closely related.
  • A family history that includes pancreatic cancer alongside other cancers in the hereditary cancer spectrum, particularly breast, ovarian, prostate, colorectal, endometrial, or melanoma.
  • Ashkenazi Jewish ancestry, given the elevated population frequency of BRCA1 and BRCA2 founder variants (covered in our Ashkenazi Jewish ancestry post).

A genetic counselor can help work through whether testing makes sense given personal medical history, family structure, age, reproductive plans, and other considerations.

What about pancreatic neuroendocrine tumors?

This is an important distinction that often goes underexplained. Pancreatic neuroendocrine tumors (pNETs) are a different type of cancer from pancreatic adenocarcinoma, even though both arise from the pancreas. The biology is different, the clinical behavior is different, and the genetic risk landscape is different.

Pancreatic NETs are most commonly associated with a different group of hereditary syndromes, including:

  • Multiple Endocrine Neoplasia type 1 (MEN1), caused by variants in the MEN1 gene
  • Von Hippel-Lindau disease (VHL), caused by variants in the VHL gene
  • Neurofibromatosis type 1 (NF1), caused by variants in the NF1 gene
  • Tuberous sclerosis complex (TSC), caused by variants in the TSC1 or TSC2 genes

A personal or family history that includes pancreatic NETs (rather than pancreatic adenocarcinoma) calls for a different testing approach. The genes that need to be evaluated may be different, and the testing recommendations and screening considerations are not the same. If your family history includes pancreatic NETs, or if you have been diagnosed with one yourself, this is a conversation worth having with a genetic counselor who can review the family history carefully and recommend the appropriate testing panel.

What is familial pancreatic cancer kindred?

This is one of the most clinically meaningful categories in hereditary pancreatic cancer, and it often surprises people. A family qualifies as a familial pancreatic cancer kindred when there are at least two first-degree relatives in the family with pancreatic cancer, and a known causative gene variant has not been identified through genetic testing.

The piece that often surprises people is how this definition includes unaffected relatives. A person qualifies for pancreatic cancer screening as part of a familial pancreatic cancer kindred if they have a first-degree relative with pancreatic cancer, and that relative in turn has their own first-degree relative with pancreatic cancer. For example, if your father had pancreatic cancer, and your paternal uncle (your father's brother) also had pancreatic cancer, this qualifies as familial pancreatic cancer kindred and you may be eligible for screening, even though you yourself have not been diagnosed and your genetic testing may be negative.

This designation matters because it reflects an important clinical reality: pancreatic cancer can cluster in families in ways that suggest an inherited factor, even when current testing technology has not been able to identify the specific gene responsible. The shared family history itself is enough of a risk signal that screening recommendations apply, regardless of whether a pathogenic variant has been found.

In practical terms, this means that if your family meets familial pancreatic cancer kindred criteria, you qualify for pancreatic cancer screening even if your genetic testing comes back negative. A negative test does not always mean a negative family history, and the family pattern itself can be a basis for ongoing surveillance.

What does pancreatic cancer screening look like?

Pancreatic cancer screening is not yet standard of care for the general population. It is, however, recommended for specific groups of people at elevated risk based on their genetic test results or family history.

Guidelines from different professional groups have moved at different speeds and do not fully agree on who should be screened. The International Cancer of the Pancreas Screening (CAPS) Consortium guidelines historically required at least one first-degree relative with pancreatic cancer for carriers of pathogenic variants in BRCA1, BRCA2, PALB2, ATM, or the Lynch syndrome genes to qualify for screening (Goggins et al., 2020). More recent guidance from NCCN and the American Society for Gastrointestinal Endoscopy (ASGE) has moved away from this family history requirement for at least some of those genes. ASGE has recommended that all people with a pathogenic BRCA1, BRCA2, or PALB2 variant be considered for pancreatic cancer screening regardless of family history, and NCCN has updated its guidance to recommend that all appropriately aged BRCA2 and ATM carriers be considered for screening regardless of family history (Sawhney et al., 2022; NCCN, 2025).

In practical terms, this means that people with pathogenic variants in the following genes are generally candidates for pancreatic cancer screening:

  • BRCA1, BRCA2, PALB2, ATM, and the Lynch syndrome genes — with the family history requirement depending on which professional group's guidance is being followed.
  • CDKN2A — with or without family history.
  • STK11 (Peutz-Jeghers syndrome) — with or without family history.
  • People in familial pancreatic cancer kindreds, as described in the section above.

Screening typically involves MRI/MRCP (magnetic resonance imaging with cholangiopancreatography) and endoscopic ultrasound (EUS), either alternated or used in combination, often starting at age 50 or 10 years younger than the youngest pancreatic cancer in the family (whichever comes first). For Peutz-Jeghers syndrome, screening may begin earlier, generally around age 35.

The goal of screening is to detect changes in the pancreas at an earlier and more treatable stage. Screening is best done at a center experienced in high-risk pancreatic surveillance, because interpretation of the imaging is nuanced and decisions about follow-up are best made by clinicians with significant experience in this area. The differences between professional guidelines are also a reason that a conversation with a genetic counselor is valuable: understanding which guidelines apply to your situation, and which screening recommendations match your specific genetic and family history profile, is part of what we are here to help with.

What does a positive genetic test result mean for treatment?

For someone diagnosed with pancreatic cancer, a positive genetic test result can directly influence treatment. The most well-established example is the use of PARP inhibitor therapy in people with germline BRCA1 or BRCA2 variants. PARP inhibitors are a class of targeted treatments that work by exploiting the DNA repair defects in tumors that carry these variants. The POLO trial established olaparib as a maintenance therapy for people with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed after first-line platinum-based chemotherapy, based on improved progression-free survival, and led to FDA approval for this use in 2019 (Kindler et al., 2022). PARP inhibitor use in people with germline PALB2 variants is an active area of research given the biological similarity to BRCA-associated cancers.

People with Lynch syndrome–associated pancreatic cancer may also be candidates for immunotherapy in some clinical scenarios, given the biological features of Lynch-associated tumors.

These are decisions made between a patient and their oncology team, but the genetic test result is what opens the door to having those conversations in the first place. This is one of the most important reasons that testing is now recommended at diagnosis rather than later in the treatment course.

What should you do next?

If you have a personal or family history that suggests pancreatic cancer risk could be elevated, the most useful first step is a genetic counseling appointment. A genetic counselor can review your personal and family history in detail, help you understand which testing approach makes the most sense for your situation, explain what different results would and would not tell you, and help you think through what screening and management would look like depending on what testing finds.

If you have recently been diagnosed with pancreatic cancer, your oncology team may already be coordinating genetic testing as part of your care. If that conversation has not happened yet, you can ask about it directly, and a genetic counselor can help interpret the results and explain what they mean for treatment and for your family.

A few other resources from our blog that may be useful:

Why the conversation matters

There is still much to learn about pancreatic cancer detection and treatment, but the ability to learn of genetic risk and begin pancreatic cancer screening is genuinely impactful for families and is crucial to bring into the conversation.

---

Talk with a ClearPath Genetic Counselor

If you have a personal or family history of pancreatic cancer and you want to understand what testing options make sense for you, or you have already had testing and want help interpreting your results, we are here to help.

Have a Question? Text or call us at (720) 799-0730 or email us at hello@clearpathgenetics.com.

---

References

Facing Our Risk of Cancer Empowered (FORCE). (2025). Hereditary pancreatic cancer and gene-specific risk pages. https://www.facingourrisk.org/

Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., Fockens, P., Gress, T. M., van Hooft, J. E., Hruban, R. H., Kastrinos, F., Klein, A., Lennon, A. M., Lucas, A., Park, W., … Bruno, M.; International Cancer of the Pancreas Screening (CAPS) Consortium. (2020). Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 69(1), 7–17.

Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J., Keller, J. J., Westerman, A. M., Scott, R. J., Lim, W., Trimbath, J. D., Giardiello, F. M., Gruber, S. B., Offerhaus, G. J., de Rooij, F. W., Wilson, J. H., Hansmann, A., Möslein, G., Royer-Pokora, B., … Houlston, R. S. (2006). Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clinical Cancer Research, 12(10), 3209–3215.

Hsu, F. C., Roberts, N. J., Childs, E., Porter, N., Rabe, K. G., Borgida, A., Ukaegbu, C., Goggins, M. G., Hruban, R. H., Zogopoulos, G., Syngal, S., Gallinger, S., Petersen, G. M., & Klein, A. P. (2021). Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene. JAMA Oncology, 7(11), 1664–1668.

Hu, C., Hart, S. N., Polley, E. C., Gnanaolivu, R., Shimelis, H., Lee, K. Y., Lilyquist, J., Na, J., Moore, R., Antwi, S. O., Bamlet, W. R., Chaffee, K. G., DiCarlo, J., Wu, Z., Samara, R., Kasi, P. M., McWilliams, R. R., Petersen, G. M., & Couch, F. J. (2018). Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA, 319(23), 2401–2409.

Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D. Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., Bordia, S., McGuinness, D., Cui, K., Locker, G. Y., & Golan, T. (2022). Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. Journal of Clinical Oncology, 40(34), 3929–3939.

National Comprehensive Cancer Network. (2025). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment — Breast, ovarian, and pancreatic. https://www.nccn.org/

Sawhney, M. S., Calderwood, A. H., Thosani, N. C., Rebbeck, T. R., Wani, S., Canto, M. I., Fishman, D. S., Golan, T., Hidalgo, M., Kwon, R. S., Riegert-Johnson, D. L., Sahani, D. V., Stoffel, E. M., Vollmer, C. M., & Qumseya, B. J.; ASGE Standards of Practice Committee. (2022). ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: Summary and recommendations. Gastrointestinal Endoscopy, 95(5), 817–826.

Vasen, H. F., Gruis, N. A., Frants, R. R., van Der Velden, P. A., Hille, E. T., & Bergman, W. (2000). Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). International Journal of Cancer, 87(6), 809–811.

Yang, X., Leslie, G., Doroszuk, A., Schneider, S., Allen, J., Decker, B., Dunning, A. M., Redman, J., Scarth, J., Plaskocinska, I., Luccarini, C., Shah, M., Pooley, K., Dorling, L., Lee, A., Adank, M. A., Adlard, J., Aittomäki, K., Andrulis, I. L., … Tischkowitz, M. (2020). Cancer risks associated with germline pathogenic variants in PALB2. Journal of Clinical Oncology, 38(7), 674–685.

---

This blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician, genetic counselor, or other qualified healthcare provider with any questions you may have regarding a medical condition or your individual health needs.